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Clostridium difficile is the most common cause of
nosocomial antibiotic-associated diarrhea
(Johnson and Gerding, 1998). Treatment with
metronidazole and vancomycin has proved ef-
fective but approximately 15-20% of patients have
recurrences (Wilcox and Spencer, 1992) that may
occur in up to 42% of patients in high-risk groups
such as the elderly (Borriello and Larson, 1981).
Recurrences may be explained by endogenous
persistence of C. difficile spores (relapse) or by
the acquisition of a new strain from an exoge-
nous source (reinfection).
This increases the costs of treatment, the risks of
cross-infection and the duration of hospitaliza-
tion. The aim of our study was to analyze C. dif-
ficile isolates obtained from patients with recur-
rent diarrhea to distinguish between relapse and
reinfection.
A total of 130 C. difficile strains isolated from 53
patients presenting recurrence of Clostridium dif-
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ficile infection (CDI) and collected over a period
of 1 year (May 2009-April 2010) were included in
this study (Table 1). A recurrence rate of 41% was
found during the period of observation. Before
CDI diagnosis, all patients were treated with pro-
ton pomp inhibitors (PPI) a known risk factor for
recurrences (Cadle et al., 2007). Multiple C. diffi-
cile-positive faeces (at least two) were obtained
from each patient during hospitalization. These
Recurrence is a major complication of Clostridium difficile-associated diarrhea and occurs in 15 to 20% of patients af-
ter discontinuation of therapy. Strains from 53 patients with Clostridium difficile recurrences were fingerprinted by PCR
ribotyping. Reinfection with a different strain occurred in 15 out of 53 patients (28,3%), while 38 patients relapsed.
These data suggest the need to perform molecular typing for implementation of infection control procedures and for
a more appropriate therapeutic strategy.
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TABLE 1 - Epidemiology of recurrent C. difficile-
associated diarrhea.
Patient No. of Time range 
population patients between 
recurrences 
Total 53 2-5 weeks
With relapse 38 
With reinfection 15
Gender (M:F) 34:19
Ward
Cardiology 18
Medicine 22
Cancer 13
patients were inpatients at a long-term facility
(ASP Istituti Milanesi Martinitt e Stelline e Pio
Albergo Trivulzio, Milan; Italy). Recurrences were
defined as patients with a resurgence of symp-
toms after cessation, at least 10 days after the first
episode. All faecal specimens from patients sus-
pected of having CDI were tested for toxin A/B
using the enzyme-linked immunosorbent assay
(ImmnunoCard Toxins A&B; Meridian) accord-
ing to the manufacturer’s instructions. 
Toxins A and B positive stools were plated on se-
lective cycloserine-cefoxitin-fructose agar plates
(CLO agar; bioMérieux, Italy) and incubated in
an anaerobic atmosphere for 48 h. Species iden-
tity was confirmed using an automatic system
(Anaerobic Card-Vitek; bioMérieux, Italy). Strains
were fingerprinted using PCR ribotyping (Bidet et
al., 1999) and toxinotyping (Rupnik et al., 1997).
DNA was extracted from a single C. difficile
colony using a Chelex resin-based commercial kit
(InstaGene Matrix; Bio-Rad) as recommended by
the manufacturer. 
For PCR ribotyping, amplification reactions were
performed in a 50 µl volume containing 1x reac-
tion buffer, 1.5 mM MgCl2, 200 µM of each dNTP
(Sigma), 50 pmol of each primer, 1.25 U of Taq
polymerase (Sigma) and 5 µl of DNA extract (or
distilled water as negative control). After a de-
naturation of 5 min at 94°C, the DNA was am-
plified by 35 cycles of 1 min at 94°C, 1 min at
57°C, and 30 s at 72°C). At the end, samples were
held at 72°C for 7 min. 
Amplification products were electrophoresed in
an 3% agarose (SeaKem LE; Lonza) and visual-
ized under UV light following ethidium bromide
staining. PCR ribotype profile analysis was car-
ried out using BioNumerics software (version 4.0;
Applied Maths). Strains were considered to be
“indistinguishable” when showed ≥97% similar-
ity and no banding differences. We compared the
patterns with those obtained by the use of clini-
cal strains with known ribotypes. For toxinotyp-
ing we followed the methods reported in the tox-
inotyping home page (http://www.mf.uni-
mb.si/mikro/tox). 
The determination of toxin genes were performed
by PCR as previously described (Kato et al., 1998)
using 5 µl of crude DNA extract. Because the
spread of hypervirulent C. difficile strains, ribo-
type 027 (Loo et al., 2005; McDonald et al., 2005)
and 078 (Goorhuis et al., 2008), the presence of bi-
nary toxin was also investigated by PCR, as pre-
viously described (Stubbs et al., 2000).
Ages of patients ranged from 76 to 91 years (86±4
years). 
All the isolates were confirmed as being toxin A
and B producers, and to belong to toxinotype 0;
no strain harboured binary-toxin gene.
During the period of study, the strains circulat-
ing in the wards of the long-term facility belonged
to 5 different ribotypes; the most frequent type, ri-
botype 018, accounted for 78% of all the strains,
followed by ribotype 002 (10%), ribotype 106
(8%), ribotype 014 (2%), and ribotype 001 (2%).
Fifteen of the 53 recurrences (28.3%) were due
to reinfection with exogenous C. difficile strains,
while 38 (71.7%) were relapses (Figure 1). Our
results are in agreement with those obtained by
Alonso et al. (2001). 
Ribotypes found during the first episode of rein-
fection were: 018 (66.7%), 002 (20%), 106 (6.7%)
and 014 (6.7%). Strains isolated from the next
episodes belonged to ribotypes 018 and 004. In
particolar ribotype 108 was found in 86.01% of
patients.
For the relapses, 26 (68.5%) samples belonged to
ribotype 018, four (10.6%) to ribotype 002, four
to ribotype 106 (10.6%), two (5.3%) to ribotype
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FIGURE 1 - PCR ribotyping of selected C. difficile isolates
from patients with recurrent CDAD. Lanes 1 and 4, and
lines 5-6, DNA-banding patterns of isolates from two pa-
tients with recurrent CDAD due to reinfection; and lanes
2-3, DNA fingerprint of one patient with relapse.
014, one (2.7%) to ribotype 186 and one (2.7%) to
ribotype 001. 
So, the patients from whom identical isolates
were recovered for various disease episodes can-
not conclusively be said to have undergone re-
lapse due to an endogenous source of the organ-
ism or therapeutic failure. It is possible that these
patients re-acquired C. difficile from the hospital
environment (even without having isolated an as-
sociated environmental strain due to the absence
of samples taken during the period under con-
sideration), or through horizontal transmission.
In fact, 17 of our patients with relapses harboured
strains with the same pattern found in other pa-
tients of the same ward. 
We therefore hypothesized that the frequency of
reinfection was probably underestimated because
of the reacquisition of the same strain from the
hospital environment. Previous reports have
shown that reinfections tend to occur later than
relapses (Barbut et al., 2000; Johnson et al., 1989).
Interestingly, all our cases of recurrences showed
no significant delay of relapse and reinfection
(Table 1). We hypothesized that in this category
of patients, it was probably due to the concomi-
tant presence of different risk factors: advanced
age, long hospital stay, serious underlying dis-
eases and continuous treatments with broad-
spectrum antibiotics and PPI. In our experience,
we can conclude that for recurrences, the time
elapsed between two or more episodes is not suf-
ficient to establish if they are reinfection or re-
lapse. So the use of methods to distinguish re-
lapses from re-infections seems essential to
choose alternative drug regimens or to implement
adequate control measures. For this purpose, ap-
propriate genotyping methods are needed.
Although Killgore et al. (2008) reported that PCR
ribotyping is not able to recognize subtypes un-
der primary types, we used this technique be-
cause is easy and rapid to perform (Bidet et al.,
1999; Bidet et al., 2000; Stubbs et al., 1999) and
shows excellent concordance and equal discrim-
inatory ability with other C. difficile typing meth-
ods such as tandem repeat sequences analysis
(Zaiß et al., 2009).
Our conclusion agree with Johnson et al.
(Johnson et al., 1989) who reported that, in order
to contain recurrent CDI, the documentation of
reinfection as opposed to relapse is important be-
cause the incidence of reinfection may be reduced
on the basis of several infection control proce-
dures (Wilcox et al., 1998); a more rational use of
antibiotics has also to be considered. The differ-
ences in environmental contamination could af-
fect the different rates of recurrences reported
from different institutions. 
In conclusion, after our study, additional infec-
tion control measures have been reinforced, in-
cluding an increase in environmental cleaning
with chlorine, bedside tables and toilet seats treat-
ment with sporicidal agents, strict regulations
about handwashing of health care workers, and
early isolation of patients with diarrhoeal illness.
Furthermore, it has been established to avoid,
when possible, the use of antibiotics shown to
have a particular predisposition to cause CDI.
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